Articles: function.
-
Cardiovascular Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Carfilzomib is a novel chemotherapy agent for the treatment of relapsed and refractory Multiple Myeloma (MM). It is a selective, irreversible proteasome inhibitor that induces apoptosis of myeloma cells. It was approved by US-FDA in July 2012. ⋯ The following authors have nothing to disclose: Sameer Chadha, Rahul Yadav, Kunal Teli, Guy Kulbak, Gerald Hollander, Jacob ShaniNo Product/Research Disclosure Information.
-
Congenital Disorder Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Primary ciliary dyskinesia(PCD) is a well-known congenital disorder manifesting in infancy to childhood in 70-80% cases, with the rest being diagnosed in their second decade. The ciliary dysfunction affects the upper and lower respiratory apparatus leading to recurrent sinus infections, pneumonias and irreversible processes including bronchiectasis usually before reaching adulthood. ⋯ The following authors have nothing to disclose: Prashanth Thalanayar, Fernando HolguinNo Product/Research Disclosure Information.
-
Mortality after lower limb amputation is high, with UK 30-day mortality rates of 9-17%. We performed a retrospective analysis of factors affecting early and late outcome after lower limb amputation for peripheral vascular disease or diabetic complications at a UK tertiary referral vascular centre between 2003 and 2010. Three hundred and thirty-nine patients (233 male), of median (IQR [range]) age 73 (62-79 [26-92]) years underwent amputation. ⋯ Anaesthetic technique was associated with long-term mortality on survival analysis (p = 0.04), but not when analysed using regression modelling. Mortality after lower limb amputation relates to patient age, ASA, out-of-hours surgery and renal dysfunction. These data support lower limb amputations' being performed during daytime hours and after modification replace with 'of ' correctable risk factors.
-
Miscellaneous Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: ICU readmissions after lung transplantation (LTx) have increased over the years, as a consequence of expanded criteria for LTx-list inclusion, with higher severity scores of patients in the list, together with the use of marginal grafts. ⋯ The following authors have nothing to disclose: Mauricio Acuña, Jordi Riera, Jordi Rello, Antonio RomanNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The ILLUMINATE study evaluated the superiority of once-daily QVA149 110/50μg, a dual bronchodilator combining the LABA indacaterol and LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500μg (SFC), in terms of efficacy, safety and tolerability in patients with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 versus SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment. ⋯ Karen Mezzi: Employee: Novartis Employee John Pallante: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.